Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Idorsia Ltd
  6. Company
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sales per Business
20192020Delta
Drugs23.82100%71.76100% +201.26%
CHF in Million
Sales per region
20192020Delta
Switzerland23.82100%71.76100% +201.26%
CHF in Million
Managers
Name Title Age Since
Jean-Paul Clozel Chief Executive Officer & Director 66 2017
AndrÚ C. Muller Chief Financial Officer & Executive Vice President 57 2017
Guy Braunstein, Dr. Executive VP & Head-Global Clinical Development 64 2017
Martine Clozel, Dr. Chief Scientific Officer & Executive VP 65 2017
Andrew C. Weiss SVP, Head-Corporate Communication & IR 52 2017
Simon Jose Chief Commercial Officer & Executive VP 56 2018
Oliver Peinelt Senior Vice President-Group General Counsel 51 2017
Alexander Khatuntsev Senior Vice President & Head-Human Resources 42 2017
Members of the board
Name Title Age Since
Mathieu Simon Chairman 65 -
Jean-Paul Clozel Chief Executive Officer & Director 66 2017
J÷rn Aldag Non-Executive Director 62 -
Michel de Rosen Non-Executive Director 70 -
Felix R. Ehrat, Dr. Non-Executive Director 64 -
Sandesh Mahatme Non-Executive Director 56 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 167,113,191 106,027,820 63.4% 0 0.0% 63.4%
Shareholders
NameEquities%
Clozel Family 48,524,853 29.1%
Rudolf Maag 8,989,167 5.40%
Fidelity Management & Research Co. LLC 6,706,635 4.03%
Artisan Partners LP 3,461,573 2.08%
Norges Bank Investment Management 3,122,495 1.88%
The Vanguard Group, Inc. 2,943,324 1.77%
UBS Asset Management Switzerland AG 2,638,163 1.58%
Southeastern Asset Management, Inc. 2,516,860 1.51%
ZŘrcher Kantonalbank (Investment Management) 2,431,326 1.46%
Vontobel Asset Management AG 2,172,067 1.30%
Company contact information
Idorsia Ltd.
Hegenheimermattweg 91
Allschwil, Basel-Landschaft (Basle Country) 4123

Phone : +41.58.844.00.00
Web : http://www.idorsia.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
IDORSIA LTD-0.39%4 767
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308
BEIGENE, LTD.22.66%33 627
GENMAB A/S15.31%27 394
ARGENX SE10.70%16 311
HUALAN BIOLOGICAL ENGINEERING INC.-9.75%10 439
NEUROCRINE BIOSCIENCES, INC.2.79%9 482
ARROWHEAD PHARMACEUTICALS, INC.-10.90%9 401
DENALI THERAPEUTICS INC.-23.71%9 051
MIRATI THERAPEUTICS, INC.-28.46%8 451
FATE THERAPEUTICS, INC.-5.21%7 951
REMEGEN CO., LTD.0.58%7 820
ACCELERON PHARMA INC.-4.01%7 722
ASCENDIS PHARMA A/S-30.65%7 555
EXELIXIS, INC.-16.64%7 340
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.39.34%6 690